Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases
Aim. To evaluate the role of polymorphisms in adrenoceptor beta 1 (ADRB1) (Arg389Gly, rs1801253) and angiotensin-converting enzyme (ACE) (I/D, rs4343) genes in assessing the effectiveness of β-blocker (carvedilol) and ACE inhibitor (enalapril) therapy in women with anthracycline-induced cardiotoxici...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian State Medical University (Tomsk)
2023-01-01
|
| Series: | Бюллетень сибирской медицины |
| Subjects: | |
| Online Access: | https://bulletin.ssmu.ru/jour/article/view/5020 |
| _version_ | 1797872791791337472 |
|---|---|
| author | E. V. Grakova K. V. Kopeva S. N. Shilov E. N. Berezikova A. A. Popova M. N. Neupokoeva E. T. Ratushnyak V. V. Kalyuzhin A. T. Teplyakov |
| author_facet | E. V. Grakova K. V. Kopeva S. N. Shilov E. N. Berezikova A. A. Popova M. N. Neupokoeva E. T. Ratushnyak V. V. Kalyuzhin A. T. Teplyakov |
| author_sort | E. V. Grakova |
| collection | DOAJ |
| description | Aim. To evaluate the role of polymorphisms in adrenoceptor beta 1 (ADRB1) (Arg389Gly, rs1801253) and angiotensin-converting enzyme (ACE) (I/D, rs4343) genes in assessing the effectiveness of β-blocker (carvedilol) and ACE inhibitor (enalapril) therapy in women with anthracycline-induced cardiotoxicity (AIC) without prior cardiovascular diseases (CVD) during 12-month follow-up.Materials and methods. A total of 82 women (average age 45.0 (42.0; 50.0) years) with AIC and without prior CVD were included in the study. Echocardiography was performed and serum levels of NT-proBNP were determined at baseline and at 12 months after the enrollment. Gene polymorphisms in ADRB1 and ACE genes were evaluated by polymerase chain reaction at baseline.Results. Carriers of the G/G genotype in the ADRB1 gene and G/G genotype in the ACE (I/D, rs4343) gene showed a significant increase in left ventricular ejection fraction (LVEF), a decrease in the size of the left ventricle (LV) and left atrium (LA), and a fall in the NT-proBNP level. Carriers of other genotypes had further progression of AIC which was manifested through a decrease in LVEF and an increase in the size of LV and LA.Conclusion. Evaluation of gene polymorphisms in ADRB1 (Arg389Gly, rs1801253) and ACE (I/D, rs4343) genes may be recommended before treatment initiation for AIC in women without prior CVD to determine who will benefit from carvedilol and enalapril therapy, as well as to identify a priority group of patients for personalized intensification and optimization of treatment for decreasing development of adverse cardiovascular events. |
| first_indexed | 2024-04-10T01:05:44Z |
| format | Article |
| id | doaj.art-d716a486ddc14e388bcef4acedb28443 |
| institution | Directory Open Access Journal |
| issn | 1682-0363 1819-3684 |
| language | English |
| last_indexed | 2024-04-10T01:05:44Z |
| publishDate | 2023-01-01 |
| publisher | Siberian State Medical University (Tomsk) |
| record_format | Article |
| series | Бюллетень сибирской медицины |
| spelling | doaj.art-d716a486ddc14e388bcef4acedb284432023-03-13T09:58:28ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842023-01-01214445310.20538/1682-0363-2022-4-44-532940Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseasesE. V. Grakova0K. V. Kopeva1S. N. Shilov2E. N. Berezikova3A. A. Popova4M. N. Neupokoeva5E. T. Ratushnyak6V. V. Kalyuzhin7A. T. Teplyakov8Научно-исследовательский институт (НИИ) кардиологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наукНаучно-исследовательский институт (НИИ) кардиологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наукНовосибирский государственный медицинский университет (НГМУ)Новосибирский государственный медицинский университет (НГМУ)Новосибирский государственный медицинский университет (НГМУ)Новосибирский государственный медицинский университет (НГМУ)Новосибирский государственный медицинский университет (НГМУ)Сибирский государственный медицинский университет (СибГМУ)Научно-исследовательский институт (НИИ) кардиологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наукAim. To evaluate the role of polymorphisms in adrenoceptor beta 1 (ADRB1) (Arg389Gly, rs1801253) and angiotensin-converting enzyme (ACE) (I/D, rs4343) genes in assessing the effectiveness of β-blocker (carvedilol) and ACE inhibitor (enalapril) therapy in women with anthracycline-induced cardiotoxicity (AIC) without prior cardiovascular diseases (CVD) during 12-month follow-up.Materials and methods. A total of 82 women (average age 45.0 (42.0; 50.0) years) with AIC and without prior CVD were included in the study. Echocardiography was performed and serum levels of NT-proBNP were determined at baseline and at 12 months after the enrollment. Gene polymorphisms in ADRB1 and ACE genes were evaluated by polymerase chain reaction at baseline.Results. Carriers of the G/G genotype in the ADRB1 gene and G/G genotype in the ACE (I/D, rs4343) gene showed a significant increase in left ventricular ejection fraction (LVEF), a decrease in the size of the left ventricle (LV) and left atrium (LA), and a fall in the NT-proBNP level. Carriers of other genotypes had further progression of AIC which was manifested through a decrease in LVEF and an increase in the size of LV and LA.Conclusion. Evaluation of gene polymorphisms in ADRB1 (Arg389Gly, rs1801253) and ACE (I/D, rs4343) genes may be recommended before treatment initiation for AIC in women without prior CVD to determine who will benefit from carvedilol and enalapril therapy, as well as to identify a priority group of patients for personalized intensification and optimization of treatment for decreasing development of adverse cardiovascular events.https://bulletin.ssmu.ru/jour/article/view/5020антрациклин-индуцированная кардиотоксичностьсердечная недостаточностьполиморфизмы геновβ-адреноблокаторингибитор ангиотензинпревращающего фермента |
| spellingShingle | E. V. Grakova K. V. Kopeva S. N. Shilov E. N. Berezikova A. A. Popova M. N. Neupokoeva E. T. Ratushnyak V. V. Kalyuzhin A. T. Teplyakov Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases Бюллетень сибирской медицины антрациклин-индуцированная кардиотоксичность сердечная недостаточность полиморфизмы генов β-адреноблокатор ингибитор ангиотензинпревращающего фермента |
| title | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_full | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_fullStr | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_full_unstemmed | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_short | Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases |
| title_sort | pharmacogenetics in treatment of anthracycline induced cardiotoxicity in women without prior cardiovascular diseases |
| topic | антрациклин-индуцированная кардиотоксичность сердечная недостаточность полиморфизмы генов β-адреноблокатор ингибитор ангиотензинпревращающего фермента |
| url | https://bulletin.ssmu.ru/jour/article/view/5020 |
| work_keys_str_mv | AT evgrakova pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT kvkopeva pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT snshilov pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT enberezikova pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT aapopova pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT mnneupokoeva pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT etratushnyak pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT vvkalyuzhin pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases AT atteplyakov pharmacogeneticsintreatmentofanthracyclineinducedcardiotoxicityinwomenwithoutpriorcardiovasculardiseases |